Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Moberg Pharma licenses MOB-015 to Karo Healthcare for marketing in 19 European markets

Moberg Pharma has signed an exclusive licensing agreement with Karo Healthcare to market its onychomycosis treatment MOB-015 (Terclara) in 19 European markets, including the United Kingdom. Karo will handle marketing, distribution and sales in Europe; the deal includes royalties and payments for supplied products, but financial details were not disclosed. The territory covers about 500 million people and includes 11 countries where Terclara is already approved but not yet launched. MOB-015 is a topical terbinafine formulation with a reported mycological cure rate of 76% and will, where possible, be marketed under the Lamisil brand; Karo is backed by KKR. Moberg emphasizes it will remain commercially active in other regions, notably the US, and analysis indicates it has solid liquidity despite not being profitable last year. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2019, Moberg Pharma Aktie ha già distribuito 41,79 € di dividendi. L'ultimo pagamento è avvenuto a novembre 2019.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Moberg Pharma Aktie ha registrato ricavi pari a 520,31K € e un utile netto di -296,07K €

(EUR)	giu 2026	YoY
Ricavi	520,31K	61,22%
Utile lordo	340,01K	123,25%
Utile netto	-296,07K	55,38%
EBITDA	-618,03K	16,50%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	44,9 Mln €
Numero di azioni	47,18 Mln
Massimo/minimo a 52 settimane	1,27 € - 0,68 €
Dividendi	No
Beta	0,74
Rapporto P/E	-23,10
Rapporto PEG	-0,18
Rapporto P/B	0,75
Rapporto P/S	29,84

Profilo aziendale

Moberg Pharma AB (publ), ein pharmazeutisches Unternehmen, entwickelt und vermarktet medizinische Produkte in Europa, den Vereinigten Staaten und international. Es entwickelt MOB-015, das eine klinische Studie der Phase III für die Behandlung von Nagelpilz abgeschlossen hat. Das Unternehmen war früher unter dem Namen Moberg Derma AB (publ) bekannt und änderte im Mai 2013 seinen Namen in Moberg Pharma AB (publ). Moberg Pharma AB (publ) wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Bromma, Schweden.